Colin J. B. Harvey
Colin J. B. Harvey has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Chaitan Khosla
Stanford ChEM-H (Chemistry, Engineering and Medicine for Human Health), Stanford University, Palo Alto, CA 94304, USA
4 shared publicationsJian Li
From the Department of Biochemistry, Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California 94304
4 shared publicationsJoe Horecka
From the Department of Biochemistry, Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California 94304
4 shared publicationsMaureen E. Hillenmeyer
From the Department of Biochemistry, Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California 94304
4 shared publicationsUlrich Schlecht
From the Department of Biochemistry, Stanford Genome Technology Center, Stanford University School of Medicine, Palo Alto, California 94304
4 shared publications- Chaitan Khosla
Department of Chemistry, Stanford University, Stanford, California 94305, USA
3 shared publications
Latest Publications
- Open Access
- 31 January 2026
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 12 (2) , 197-207
An Antifungal with a Novel Mechanism of Action Discovered via Resistance Gene-Guided Genome Mining
Invasive fungal infections claim over two million lives annually, a problem exacerbated by rising resistance to current antifungal treatments and an increasing population of immunocompromised individuals. Despite this, antifungal drug development has stagnated, with few novel agents and fewer novel targets explored in recent decades. Here, we validate acetolactate synthase (ALS), an enzyme critical for branched-chain amino acid biosynthesis and absent in humans, as a promising target for new therapeutics. Using resistance gene-guided genome mining, we discovered a biosynthetic gene cluster in Aspergillus terreus encoding HB-35018 (1), a novel spiro-cis-decalin tetramic acid that potently inhibits ALS. Biochemical and antifungal assays demonstrate that 1 surpasses existing ALS inhibitors in efficacy against Aspergillus fumigatus and other pathogenic fungi. Structural studies via cryo-electron microscopy reveal a unique covalent binding interaction between compound 1 and ALS, distinct from known inhibitors, and finally, we demonstrate that ALS is essential for virulence in a mouse model of invasive aspergillosis. These findings position ALS as a promising target for antifungal development and demonstrate the potential of resistance gene-guided genome mining for antifungal discovery.
- 31 January 2026
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 12 (2) , 197-207
Open AccessAn Antifungal with a Novel Mechanism of Action Discovered via Resistance Gene-Guided Genome Mining
Invasive fungal infections claim over two million lives annually, a problem exacerbated by rising resistance to current antifungal treatments and an increasing population of immunocompromised individuals. Despite this, antifungal drug development has stagnated, with few novel agents and fewer novel targets explored in recent decades. Here, we validate acetolactate synthase (ALS), an enzyme critical for branched-chain amino acid biosynthesis and absent in humans, as a promising target for new therapeutics. Using resistance gene-guided genome mining, we discovered a biosynthetic gene cluster in Aspergillus terreus encoding HB-35018 (1), a novel spiro-cis-decalin tetramic acid that potently inhibits ALS. Biochemical and antifungal assays demonstrate that 1 surpasses existing ALS inhibitors in efficacy against Aspergillus fumigatus and other pathogenic fungi. Structural studies via cryo-electron microscopy reveal a unique covalent binding interaction between compound 1 and ALS, distinct from known inhibitors, and finally, we demonstrate that ALS is essential for virulence in a mouse model of invasive aspergillosis. These findings position ALS as a promising target for antifungal development and demonstrate the potential of resistance gene-guided genome mining for antifungal discovery.
- Open Access
An antifungal with a novel mechanism of action discovered via resistance gene-guided genome mining
Invasive fungal infections claim over two million lives annually, a problem exacerbated by rising resistance to current antifungal treatments and an increasing population of immunocompromised individuals. Despite this, antifungal drug development has stagnated, with few novel agents and fewer novel targets explored in recent decades. Here, we validate acetolactate synthase (ALS), an enzyme critical for branched-chain amino acid biosynthesis and absent in humans, as a promising target for new therapeutics. Using resistance gene-guided genome mining, we discovered a biosynthetic gene cluster in Aspergillus terreus encoding HB-35018 ( 1) , a novel spiro- cis -decalin tetramic acid that potently inhibits ALS. Biochemical and antifungal assays demonstrate that 1 surpasses existing ALS inhibitors in efficacy against Aspergillus fumigatus and other pathogenic fungi. Structural studies via cryo-electron microscopy reveal a unique covalent binding interaction between compound 1 and ALS, distinct from known inhibitors and finally, we demonstrate that ALS is essential for the virulence in a mouse model of invasive aspergillosis. These findings position ALS as a promising target for antifungal development and demonstrate the potential of resistance gene-guided genome mining for antifungal discovery.
Open AccessAn antifungal with a novel mechanism of action discovered via resistance gene-guided genome mining
Invasive fungal infections claim over two million lives annually, a problem exacerbated by rising resistance to current antifungal treatments and an increasing population of immunocompromised individuals. Despite this, antifungal drug development has stagnated, with few novel agents and fewer novel targets explored in recent decades. Here, we validate acetolactate synthase (ALS), an enzyme critical for branched-chain amino acid biosynthesis and absent in humans, as a promising target for new therapeutics. Using resistance gene-guided genome mining, we discovered a biosynthetic gene cluster in Aspergillus terreus encoding HB-35018 ( 1) , a novel spiro- cis -decalin tetramic acid that potently inhibits ALS. Biochemical and antifungal assays demonstrate that 1 surpasses existing ALS inhibitors in efficacy against Aspergillus fumigatus and other pathogenic fungi. Structural studies via cryo-electron microscopy reveal a unique covalent binding interaction between compound 1 and ALS, distinct from known inhibitors and finally, we demonstrate that ALS is essential for the virulence in a mouse model of invasive aspergillosis. These findings position ALS as a promising target for antifungal development and demonstrate the potential of resistance gene-guided genome mining for antifungal discovery.
- Open Access
- 16 June 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (25) , 21284-21289
Resistance Gene-Guided Genome Mining Reveals RPL10 as the Target of Ligustrone A
The ribosome is essential for protein synthesis and targeting its function serves as a platform for many therapies. Resistance gene-guided genome mining for a priori target identification has emerged as a useful workflow in natural product drug discovery, allowing for identification of a compound's target before the time-consuming work of isolation and characterization is performed. In this work, we identify the previously unknown lig biosynthetic gene cluster (BGC) which contains a predicted resistance gene that shares sequence identity with the gene for human ribosomal protein RPL10. Through both heterologous expression and in situ BGC engineering, we identify ligustrone A (1) as this BGC's product. Utilizing chemical genetics and chemoproteomics, we validate that 1 engages RPL10. Taken together, via resistance gene-guided mining we both discover a new target for a known natural product and elucidate its biosynthesis.
- 16 June 2025
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (25) , 21284-21289
Open AccessResistance Gene-Guided Genome Mining Reveals RPL10 as the Target of Ligustrone A
The ribosome is essential for protein synthesis and targeting its function serves as a platform for many therapies. Resistance gene-guided genome mining for a priori target identification has emerged as a useful workflow in natural product drug discovery, allowing for identification of a compound's target before the time-consuming work of isolation and characterization is performed. In this work, we identify the previously unknown lig biosynthetic gene cluster (BGC) which contains a predicted resistance gene that shares sequence identity with the gene for human ribosomal protein RPL10. Through both heterologous expression and in situ BGC engineering, we identify ligustrone A (1) as this BGC's product. Utilizing chemical genetics and chemoproteomics, we validate that 1 engages RPL10. Taken together, via resistance gene-guided mining we both discover a new target for a known natural product and elucidate its biosynthesis.
- Open Access
- 20 November 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (48)
Resistance gene–guided genome mining reveals the roseopurpurins as inhibitors of cyclin-dependent kinases
With the significant increase in the availability of microbial genome sequences in recent years, resistance gene–guided genome mining has emerged as a powerful approach for identifying natural products with specific bioactivities. Here, we present the use of this approach to reveal the roseopurpurins as potent inhibitors of cyclin-dependent kinases (CDKs), a class of cell cycle regulators implicated in multiple cancers. We identified a biosynthetic gene cluster (BGC) with a putative resistance gene with homology to human CDK2. Using targeted gene disruption and transcription factor overexpression in Aspergillus uvarum , and heterologous expression of the BGC in Aspergillus nidulans, we demonstrated that roseopurpurin C ( 1 ) is produced by this cluster and characterized its biosynthesis. We determined the potency, specificity, and mechanism of action of 1 as well as multiple intermediates and shunt products produced from the BGC. We show that 1 inhibits human CDK2 with a K iapp of 44 nM, demonstrates selectivity for clinically relevant members of the CDK family, and induces G1 cell cycle arrest in HCT116 cells. Structural analysis of 1 complexed with CDK2 revealed the molecular basis of ATP-competitive inhibition.
- 20 November 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (48)
Open AccessResistance gene–guided genome mining reveals the roseopurpurins as inhibitors of cyclin-dependent kinases
With the significant increase in the availability of microbial genome sequences in recent years, resistance gene–guided genome mining has emerged as a powerful approach for identifying natural products with specific bioactivities. Here, we present the use of this approach to reveal the roseopurpurins as potent inhibitors of cyclin-dependent kinases (CDKs), a class of cell cycle regulators implicated in multiple cancers. We identified a biosynthetic gene cluster (BGC) with a putative resistance gene with homology to human CDK2. Using targeted gene disruption and transcription factor overexpression in Aspergillus uvarum , and heterologous expression of the BGC in Aspergillus nidulans, we demonstrated that roseopurpurin C ( 1 ) is produced by this cluster and characterized its biosynthesis. We determined the potency, specificity, and mechanism of action of 1 as well as multiple intermediates and shunt products produced from the BGC. We show that 1 inhibits human CDK2 with a K iapp of 44 nM, demonstrates selectivity for clinically relevant members of the CDK family, and induces G1 cell cycle arrest in HCT116 cells. Structural analysis of 1 complexed with CDK2 revealed the molecular basis of ATP-competitive inhibition.
- Open Access
- 1 January 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (4) , 1257-1266
A biosensor-based approach reveals links between efflux pump expression and cell cycle regulation in pleiotropic drug resistance of yeast
- 1 January 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (4) , 1257-1266
Open AccessA biosensor-based approach reveals links between efflux pump expression and cell cycle regulation in pleiotropic drug resistance of yeast
- Top Cited PapersOpen Access
- 18 April 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (4) , eaar5459
HEx: A heterologous expression platform for the discovery of fungal natural products
For decades, fungi have been a source of U.S. Food and Drug Administration–approved natural products such as penicillin, cyclosporine, and the statins. Recent breakthroughs in DNA sequencing suggest that millions of fungal species exist on Earth, with each genome encoding pathways capable of generating as many as dozens of natural products. However, the majority of encoded molecules are difficult or impossible to access because the organisms are uncultivable or the genes are transcriptionally silent. To overcome this bottleneck in natural product discovery, we developed the HEx (Heterologous EXpression) synthetic biology platform for rapid, scalable expression of fungal biosynthetic genes and their encoded metabolites in Saccharomyces cerevisiae. We applied this platform to 41 fungal biosynthetic gene clusters from diverse fungal species from around the world, 22 of which produced detectable compounds. These included novel compounds with unexpected biosynthetic origins, particularly from poorly studied species. This result establishes the HEx platform for rapid discovery of natural products from any fungal species, even those that are uncultivable, and opens the door to discovery of the next generation of natural products.
- 18 April 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 4 (4) , eaar5459
Top Cited PapersOpen AccessHEx: A heterologous expression platform for the discovery of fungal natural products
For decades, fungi have been a source of U.S. Food and Drug Administration–approved natural products such as penicillin, cyclosporine, and the statins. Recent breakthroughs in DNA sequencing suggest that millions of fungal species exist on Earth, with each genome encoding pathways capable of generating as many as dozens of natural products. However, the majority of encoded molecules are difficult or impossible to access because the organisms are uncultivable or the genes are transcriptionally silent. To overcome this bottleneck in natural product discovery, we developed the HEx (Heterologous EXpression) synthetic biology platform for rapid, scalable expression of fungal biosynthetic genes and their encoded metabolites in Saccharomyces cerevisiae. We applied this platform to 41 fungal biosynthetic gene clusters from diverse fungal species from around the world, 22 of which produced detectable compounds. These included novel compounds with unexpected biosynthetic origins, particularly from poorly studied species. This result establishes the HEx platform for rapid discovery of natural products from any fungal species, even those that are uncultivable, and opens the door to discovery of the next generation of natural products.
- Open Access
Dissection of yeast pleiotropic drug resistance regulation reveals links between cell cycle regulation and control of drug pump expression
Summary: Eukaryotes utilize a highly-conserved set of drug efflux transporters to confer pleiotropic drug resistance (PDR). Despite decades of effort interrogating this process, multiple aspects of the PDR process, in particular PDR regulation, remain mysterious. In order to interrogate the regulation of this critical process, we have developed a small-molecule responsive biosensor that couples PDR transcriptional induction to growth rate in Saccharomyces cerevisiae . We applied this system to genome-wide screens for potential PDR regulators using the homozygous diploid deletion collection. These screens identified and characterized a series of genes with significant but previously uncharacterized roles in the modulation of the yeast PDR in addition to recapitulating previously-known factors involved in PDR regulation. Furthermore, we demonstrate that disruptions of the mitotic spindle checkpoint assembly lead to elevated PDR response in response to exposure to certain compounds. These results not only establish our biosensor system as a viable tool to investigate PDR in high-throughput, but also uncovers novel control mechanisms governing PDR response and a previously uncharacterized link between this process and cell cycle regulation. Significance: Pleiotropic drug resistance (PDR) is a conserved mechanism by which cells utilize membrane bound pumps to transport chemicals out of the cell. Here, we develop a growth-based biosensor system in yeast that enables high-throughput identification of factors that transcriptionally regulate PDR. Among the novel PDR regulators identified here, we show that spindle assembly checkpoint (SAC) proteins, which are important for cell cycle regulation, inhibit hyperactivation of PDR upon drug treatment. This result provides insights into PDR regulation, as well as potential targets for therapeutic intervention, particularly in chemoresistant cancers where the cell cycle regulation is often disrupted.
Open AccessDissection of yeast pleiotropic drug resistance regulation reveals links between cell cycle regulation and control of drug pump expression
Summary: Eukaryotes utilize a highly-conserved set of drug efflux transporters to confer pleiotropic drug resistance (PDR). Despite decades of effort interrogating this process, multiple aspects of the PDR process, in particular PDR regulation, remain mysterious. In order to interrogate the regulation of this critical process, we have developed a small-molecule responsive biosensor that couples PDR transcriptional induction to growth rate in Saccharomyces cerevisiae . We applied this system to genome-wide screens for potential PDR regulators using the homozygous diploid deletion collection. These screens identified and characterized a series of genes with significant but previously uncharacterized roles in the modulation of the yeast PDR in addition to recapitulating previously-known factors involved in PDR regulation. Furthermore, we demonstrate that disruptions of the mitotic spindle checkpoint assembly lead to elevated PDR response in response to exposure to certain compounds. These results not only establish our biosensor system as a viable tool to investigate PDR in high-throughput, but also uncovers novel control mechanisms governing PDR response and a previously uncharacterized link between this process and cell cycle regulation. Significance: Pleiotropic drug resistance (PDR) is a conserved mechanism by which cells utilize membrane bound pumps to transport chemicals out of the cell. Here, we develop a growth-based biosensor system in yeast that enables high-throughput identification of factors that transcriptionally regulate PDR. Among the novel PDR regulators identified here, we show that spindle assembly checkpoint (SAC) proteins, which are important for cell cycle regulation, inhibit hyperactivation of PDR upon drug treatment. This result provides insights into PDR regulation, as well as potential targets for therapeutic intervention, particularly in chemoresistant cancers where the cell cycle regulation is often disrupted.
- Open Access
HEx: a heterologous expression platform for the discovery of fungal natural products
For decades, fungi have been a source of FDA-approved natural products such as penicillin, cyclosporine, and the statins. Recent breakthroughs in DNA sequencing suggest that millions of fungal species exist on Earth with each genome encoding pathways capable of generating as many as dozens of natural products. However, the majority of encoded molecules are difficult or impossible to access because the organisms are uncultivable or the genes are transcriptionally silent. To overcome this bottleneck in natural product discovery, we developed the HEx (Heterologous EXpression) synthetic biology platform for rapid, scalable expression of fungal biosynthetic genes and their encoded metabolites in Saccharomyces cerevisiae . We applied this platform to 41 fungal biosynthetic gene clusters from diverse fungal species from around the world, 22 of which produced detectable compounds. These included novel compounds with unexpected biosynthetic origins, particularly from poorly studied species. This result establishes the HEx platform for rapid discovery of natural products from any fungal species, even those that are uncultivable, and opens the door to discovery of the next generation of natural products. Summary: Here we present the largest scale effort reported to date toward the complete refactoring and heterologous expression of fungal biosynthetic gene clusters utilizing HEx, a novel synthetic biology platform.
Open AccessHEx: a heterologous expression platform for the discovery of fungal natural products
For decades, fungi have been a source of FDA-approved natural products such as penicillin, cyclosporine, and the statins. Recent breakthroughs in DNA sequencing suggest that millions of fungal species exist on Earth with each genome encoding pathways capable of generating as many as dozens of natural products. However, the majority of encoded molecules are difficult or impossible to access because the organisms are uncultivable or the genes are transcriptionally silent. To overcome this bottleneck in natural product discovery, we developed the HEx (Heterologous EXpression) synthetic biology platform for rapid, scalable expression of fungal biosynthetic genes and their encoded metabolites in Saccharomyces cerevisiae . We applied this platform to 41 fungal biosynthetic gene clusters from diverse fungal species from around the world, 22 of which produced detectable compounds. These included novel compounds with unexpected biosynthetic origins, particularly from poorly studied species. This result establishes the HEx platform for rapid discovery of natural products from any fungal species, even those that are uncultivable, and opens the door to discovery of the next generation of natural products. Summary: Here we present the largest scale effort reported to date toward the complete refactoring and heterologous expression of fungal biosynthetic gene clusters utilizing HEx, a novel synthetic biology platform.
- 14 June 2017
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 56 (32) , 9556-9560
Reversible Product Release and Recapture by a Fungal Polyketide Synthase Using a Carnitine Acyltransferase Domain
Fungal polyketides have significant biological activities, yet the biosynthesis by highly reducing polyketide synthases (HRPKSs) remains enigmatic. An uncharacterized group of HRPKSs was found to contain a C‐terminal domain with significant homology to carnitine O‐acyltransferase (cAT). Characterization of one such HRPKS (Tv6‐931) from Trichoderma virens showed that the cAT domain is capable of esterifying the polyketide product with polyalcohol nucleophiles. This process is readily reversible, as confirmed through the holo ACP‐dependent transesterification of the released product. The methyltransferase (MT) domain of Tv6‐931 can perform two consecutive α‐methylation steps on the last β‐keto intermediate to yield an α,α‐gem‐dimethyl product, a new programing feature among HRPKSs. Recapturing of the released product by cAT domain is suggested to facilitate complete gem‐dimethylation by the MT.
- 14 June 2017
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 56 (32) , 9556-9560
Reversible Product Release and Recapture by a Fungal Polyketide Synthase Using a Carnitine Acyltransferase Domain
Fungal polyketides have significant biological activities, yet the biosynthesis by highly reducing polyketide synthases (HRPKSs) remains enigmatic. An uncharacterized group of HRPKSs was found to contain a C‐terminal domain with significant homology to carnitine O‐acyltransferase (cAT). Characterization of one such HRPKS (Tv6‐931) from Trichoderma virens showed that the cAT domain is capable of esterifying the polyketide product with polyalcohol nucleophiles. This process is readily reversible, as confirmed through the holo ACP‐dependent transesterification of the released product. The methyltransferase (MT) domain of Tv6‐931 can perform two consecutive α‐methylation steps on the last β‐keto intermediate to yield an α,α‐gem‐dimethyl product, a new programing feature among HRPKSs. Recapturing of the released product by cAT domain is suggested to facilitate complete gem‐dimethylation by the MT.
- Open Access
- 12 April 2017
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 70 (7) , 859-863
Heterologous expression of diverse propionyl-CoA carboxylases affects polyketide production in Escherichia coli
- 12 April 2017
- Published by Springer Nature in The Journal of Antibiotics
- Vol. 70 (7) , 859-863
Open AccessHeterologous expression of diverse propionyl-CoA carboxylases affects polyketide production in Escherichia coli